189 related articles for article (PubMed ID: 19035968)
1. Plasma lipids and inflammation in active inflammatory bowel diseases.
Romanato G; Scarpa M; Angriman I; Faggian D; Ruffolo C; Marin R; Zambon S; Basato S; Zanoni S; Filosa T; Pilon F; Manzato E
Aliment Pharmacol Ther; 2009 Feb; 29(3):298-307. PubMed ID: 19035968
[TBL] [Abstract][Full Text] [Related]
2. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
[TBL] [Abstract][Full Text] [Related]
3. Body composition in patients with inflammatory bowel disease: a population-based study.
Jahnsen J; Falch JA; Mowinckel P; Aadland E
Am J Gastroenterol; 2003 Jul; 98(7):1556-62. PubMed ID: 12873577
[TBL] [Abstract][Full Text] [Related]
4. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase.
Rocha R; Santana GO; Almeida N; Lyra AC
Br J Nutr; 2009 Mar; 101(5):676-9. PubMed ID: 18631418
[TBL] [Abstract][Full Text] [Related]
5. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
Ludwiczek O; Vannier E; Borggraefe I; Kaser A; Siegmund B; Dinarello CA; Tilg H
Clin Exp Immunol; 2004 Nov; 138(2):323-9. PubMed ID: 15498044
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
[TBL] [Abstract][Full Text] [Related]
8. Elevated concentrations of linoleic acid in erythrocyte membrane phospholipids in patients with inflammatory bowel disease.
Ueda Y; Kawakami Y; Kunii D; Okada H; Azuma M; Le DS; Yamamoto S
Nutr Res; 2008 Apr; 28(4):239-44. PubMed ID: 19083414
[TBL] [Abstract][Full Text] [Related]
9. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
[TBL] [Abstract][Full Text] [Related]
10. Association of n-3 and n-6 long-chain polyunsaturated fatty acids in plasma lipid classes with inflammatory bowel diseases.
Figler M; Gasztonyi B; Cseh J; Horváth G; Kisbenedek AG; Bokor S; Decsi T
Br J Nutr; 2007 Jun; 97(6):1154-61. PubMed ID: 17381967
[TBL] [Abstract][Full Text] [Related]
11. Saliva Interleukin-6 in patients with inflammatory bowel disease.
Aleksandra Nielsen A; Nederby Nielsen J; Schmedes A; Brandslund I; Hey H
Scand J Gastroenterol; 2005 Dec; 40(12):1444-8. PubMed ID: 16316893
[TBL] [Abstract][Full Text] [Related]
12. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease.
Kobayashi T; Okamoto S; Hisamatsu T; Kamada N; Chinen H; Saito R; Kitazume MT; Nakazawa A; Sugita A; Koganei K; Isobe K; Hibi T
Gut; 2008 Dec; 57(12):1682-9. PubMed ID: 18653729
[TBL] [Abstract][Full Text] [Related]
13. Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis.
Lampinen M; Backman M; Winqvist O; Rorsman F; Rönnblom A; Sangfelt P; Carlson M
J Leukoc Biol; 2008 Dec; 84(6):1392-9. PubMed ID: 18801925
[TBL] [Abstract][Full Text] [Related]
14. [Lipids and total bile acids in the blood of patients with inflammatory bowel diseases].
Kostić N; Bozanić M; Cvetković R; Adamov A
Srp Arh Celok Lek; 1990; 118(1-2):43-6. PubMed ID: 2218731
[TBL] [Abstract][Full Text] [Related]
15. Essential fatty acid depletion in children with inflammatory bowel disease.
Socha P; Ryzko J; Koletzko B; Celinska-Cedro D; Woynarowski M; Czubkowski P; Socha J
Scand J Gastroenterol; 2005 May; 40(5):573-7. PubMed ID: 16036510
[TBL] [Abstract][Full Text] [Related]
16. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.
Czub E; Herzig KH; Szaflarska-Popawska A; Kiehne K; Socha P; Woś H; Kamińska B; Błaszczyński M; Cichy W; Bała G; Brodzicki J; Grzybowska-Chlebowczyk U; Walkowiak J
Scand J Gastroenterol; 2007 Oct; 42(10):1147-50. PubMed ID: 17852864
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire.
Casellas F; Alcalá MJ; Prieto L; Miró JR; Malagelada JR
Am J Gastroenterol; 2004 Mar; 99(3):457-61. PubMed ID: 15056085
[TBL] [Abstract][Full Text] [Related]
18. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
[TBL] [Abstract][Full Text] [Related]
19. High plasma osteopontin levels in patients with inflammatory bowel disease.
Mishima R; Takeshima F; Sawai T; Ohba K; Ohnita K; Isomoto H; Omagari K; Mizuta Y; Ozono Y; Kohno S
J Clin Gastroenterol; 2007 Feb; 41(2):167-72. PubMed ID: 17245215
[TBL] [Abstract][Full Text] [Related]
20. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.
Guimbaud R; Bertrand V; Chauvelot-Moachon L; Quartier G; Vidon N; Giroud JP; Couturier D; Chaussade S
Am J Gastroenterol; 1998 Dec; 93(12):2397-404. PubMed ID: 9860399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
